The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...
The enzyme replacement therapy (ERT) market is projected to grow significantly, rising from US$ 10,707.6 million in ...
WashU Medicine researcher Patricia Dickson, MD, studies rare genetic diseases called lysosomal storage disorders. Dickson, ...
Hosted on MSN7d
New Research Sheds Light on How Cells Manage Fat RecyclingAccumulation of fat molecules is detrimental to the cell. Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have made a breakthrough in ...
Augustine Therapeutics appoints Gerhard Koenigas Chief Executive Officer as Company Prepares to Enter the ClinicIndustry veteran Gerhard Koenig, ...
8d
Torrey Pines Investment, a specialty life-science investment company based in San Diego, CA, and Oost NL, a regional development agency supporting innovation-driven companies, announced the pre-seed ...
Accumulation of fat molecules is detrimental to the cell. Researchers have made a breakthrough in understanding how our cells manage to stay healthy by recycling important fat molecules. Their study ...
Accumulation of fat molecules is detrimental to the cell. Researchers from the Yong Loo Lin School of Medicine, National ...
Accumulation of fat molecules is detrimental to the cell. Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have made a breakthrough in ...
LCA-0321 is a LYTAC degrader designed to specifically bind and rapidly deplete anti-TSHR autoantibodies, the underlying cause of Graves’ disease and its extrathyroidal manifestations, including ...
Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback